| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6248357 | Transplantation Proceedings | 2012 | 4 Pages |
Abstract
Surprising differences in survival and tumor recurrence rates were observed among the mTORi-treated group compared with controls. Switching from CNI to mTORi immunosuppressant therapy appeared to be safe. It seems to be reasonable to employ this strategy in liver transplant patients with primary hepatic or “de novo” neoplasms.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
J.M. Álamo, C. Bernal, L.M. MarÃn, G. Suárez, J. Serrano, L. Barrera, J.M. Sousa, F.J. Padillo, M.A. Gómez-Bravo,